https://www.selleckchem.com/products/agk2.html
4% probabilities of being cost-effective at a cost-effectiveness threshold of €30,000/QALY. The Expected Incremental Benefit was €95.16 and the Population Expected Value of Perfect Information was €8.6 million, implying that additional research is likely to be worthwhile. At a median 6-year follow up, the treatment group had a significantly better survival rate when adjusting for late effect (P = 0.039). Our findings provide the first evidence to inform decisions about funding and reimbursement of ONS in combination with nutritional counse
Like
Comment
Share
